

CORCEPT THERAPEUTICS INC  
 Form 3  
 June 12, 2008

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â PENHOET EDWARD  
 (Last) (First) (Middle)

ONE EMBARCADERO CENTER,Â SUITE 3700

(Street)

SAN FRANCISCO,Â CAÂ 94111

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)  
 06/10/2008

3. Issuer Name and Ticker or Trading Symbol  
 CORCEPT THERAPEUTICS INC [CORT]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,043,299	I	By Fund <u>(1)</u> <u>(2)</u>
Common Stock	166,491	I	By Fund <u>(1)</u> <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	------------------------------------	---------------------------------	---

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Warrant (Right to Buy)	03/25/2008	03/25/2015	Common Stock	522,960	\$ 0.125	I	By Fund <u>(1)</u> <u>(2)</u>
Warrant (right to buy)	03/25/2008	03/25/2015	Common Stock	6,607	\$ 0.125	I	By Fund <u>(1)</u> <u>(3)</u>

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
PENHOET EDWARD ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	X	X		

## Signatures

Edward Penhoet,  
Director 06/12/2008

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person, Edward Penhoet, is a director of Alta BioPharma Management II, LLC ("ABMII"), and Jean Deleage, Alix Marduel and Farah Champs are managing directors of ABMII (collectively, the "Managing Directors" and with Mr. Penhoet, the "Principals") which is the general partner of Alta BioPharma Partners II, L.P. ("ABPII"). Each of the Managing Directors is also a manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBPII" and collectively with ABPII, the "Funds"). The Principals may be deemed to share voting and investment power over the shares held by the Funds. The Reporting Person disclaims beneficial ownership of all such shares held by the Funds, except to the extent of his pecuniary interest therein.
- (1) These securities are held by Alta BioPharma Partners II, L.P. ("ABPII").
  - (2) These securities are held by Alta Embarcadero BioPharma Partners II, LLC. ("AEBPII").
  - (3) These securities are held by Alta Embarcadero BioPharma Partners II, LLC. ("AEBPII").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.